

=> d his

(FILE 'HOME' ENTERED AT 15:46:03 ON 12 JAN 2001)

FILE 'MEDLINE' ENTERED AT 15:46:24 ON 12 JAN 2001

L1 77236 S COLLAGEN  
L2 6598 S HEMOSTATIC  
L3 416 S L1 AND L2  
L4 49758 S FIBRINOGEN OR THROMBIN  
L5 121 S L4 AND L3  
L6 17017 S DEXTRAN  
L7 20 S L6 AND L2  
L8 15447 S SEPHADEX  
L9 2 S L8 AND L2

FILE 'CA' ENTERED AT 15:59:53 ON 12 JAN 2001

L10 24008 S DEXTRAN  
L11 44775 S SEPHADEX  
L12 12874 S HEMOSTATIC OR COAGULANT  
L13 165 S (L10 OR L11) AND (L12)  
L14 21735 S CROSS LINK?  
L15 0 S L10 AND L14 AND L12  
L16 23924 S EPICHLOROHYDRIN  
L17 225 S L10 AND L16  
L18 193542 S WOUND OR BLEEDING OR HEMO? OR DRESSING  
L19 28 S L17 AND L18

FILE 'WPIDS' ENTERED AT 17:09:10 ON 12 JAN 2001

L20 3673 S DEXTRAN  
L21 313239 S POLYMER  
L22 112195 S BANDAGE OR WOUND OR HEMOSTATIC  
L23 107 S L20 AND L22  
L24 108131 S CLOT? OR COAGULATION OR HEMOSTATIC  
L25 149 S L20 AND L24  
L26 158980 S DRESSING# OR BANDAGE OR COVERING#  
L27 6 S L26 AND L25

FILE 'MEDLINE' ENTERED AT 17:14:35 ON 12 JAN 2001

L28 1 S L27

FILE 'CA' ENTERED AT 17:15:39 ON 12 JAN 2001

L29 14 S L28

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	50.96	148.38
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.84	-14.00

SESSION WILL BE HELD FOR 60 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 17:23:51 ON 12 JAN 2001

FILE 'MEDLINE' ENTERED AT 15:46:24 ON 12 JAN 2001

L1        77236 S COLLAGEN  
L2        6598 S HEMOSTATIC  
L3        416 S L1 AND L2  
L4        49758 S FIBRINOGEN OR THROMBIN  
L5        121 S L4 AND L3  
L6        17017 S DEXTRAN  
L7        20 S L6 AND L2  
L8        15447 S SEPHADEX  
L9        2 S L8 AND L2

FILE 'CA' ENTERED AT 15:59:53 ON 12 JAN 2001

L10      24008 S DEXTRAN  
L11      44775 S SEPHADEX  
L12      12874 S HEMOSTATIC OR COAGULANT  
L13      165 S (L10 OR L11) AND (L12)  
L14      21735 S CROSS LINK?  
L15      0 S L10 AND L14 AND L12  
L16      23924 S EPICHLOROHYDRIN  
L17      225 S L10 AND L16  
L18      193542 S WOUND OR BLEEDING OR HEMO? OR DRESSING  
L19      28 S L17 AND L18

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	59.54	69.29
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-6.16	-6.16

SESSION WILL BE HELD FOR 60 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 16:14:55 ON 12 JAN 2001

L5 ANSWER 75 OF 121 MEDLINE  
AN 88228703 MEDLINE  
DN 88228703  
TI Topical **hemostatic** agents for dermatologic surgery [see comments].  
CM Comment in: J Dermatol Surg Oncol 1989 Mar;15(3):342-3  
AU Larson P O  
CS Division of Chemosurgery, University of Wisconsin Hospital/Clinic, Madison  
53792..  
SO JOURNAL OF DERMATOLOGIC SURGERY AND ONCOLOGY, (1988 Jun) 14 (6) 623-32.  
Ref: 61  
Journal code: HZA. ISSN: 0148-0812.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW, TUTORIAL)  
LA English  
FS Priority Journals; Cancer Journals  
EM 198809  
AB Topical **hemostatic** agents are very helpful in attaining capillary and small vessel hemostasis in dermatologic surgery. The commonly used topical **hemostatic** agents, including oxidized cellulose, absorbable gelatin, and **thrombin** are reviewed, along with newer agents such as microfibrillar **collagen**, fibrin sealants, and acrylates. Agents best suited for certain situations are recommended.  
CT Check Tags: Human; Support, Non-U.S. Gov't Administration, Topical  
\*Hemostasis, Surgical: MT, methods  
\*Hemostatics: AD, administration & dosage  
\*Skin Diseases: SU, surgery  
CN 0 (Hemostatics)

L5 ANSWER 77 OF 121 MEDLINE  
AN 88186930 MEDLINE  
DN 88186930  
TI An in vitro evaluation of the **hemostatic** activity of topical agents.  
AU Eloy R; Baguet J; Christe G; Rissoan M C; Paul J; Belleville J  
CS Unit 37 INSERM, Bron, France.  
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, (1988 Feb) 22 (2) 149-57.  
Journal code: HJJ. ISSN: 0021-9304.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 198807  
AB An in vitro method has been developed for human non-anticoagulated blood to evaluate the enhancing effect of **hemostatic** agents on both plasmatic and cellular activation of the coagulation cascade. The coagulation time and the sequential generation of fibrinopeptide A (FpA) have been used as parameters. The kinetics of generation of FpA has been modeled and mathematically analyzed using the latency time, the slope of the linear part of the curve, and the time necessary to reach half maximal amplitude of FpA in the tube. A maximal amplitude of FpA in the tube. A

very precise evaluation of the **hemostatic** activity of five different molecules, four being collagenous in nature, is given.

CT Check Tags: Comparative Study; Human

Analysis of Variance

\*Blood Coagulation: DE, drug effects

\***Collagen**: PD, pharmacology

\***Fibrinogen**: ME, metabolism

\*Fibrinopeptide A: ME, metabolism

\*Hemostatics: PD, pharmacology

Kinetics

Mathematics

Models, Biological

Regression Analysis

Whole Blood Coagulation Time

RN 25422-31-5 (Fibrinopeptide A); 9001-32-5 (**Fibrinogen**);

9007-34-5 (**Collagen**)

CN 0 (Hemostatics)